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Abstract
Background: Few data are available on the tolerance of reirradiation in patients with hepatocellular carcinoma
(HCC). This study determined the clinical parameters contributing to the development of radiation-induced liver
disease (RILD).
Methods: We included 36 patients with HCC who received 2 courses of radiotherapy (RT) to the liver. Using
α/β = 15 for tumor and α/β =8 for normal liver tissue for biologically equivalent doses in 2 Gy fractions,
mean cumulative to the hepatic tumor and normal liver were 87.7 Gy15 and 31.1 Gy8, respectively. Hepatic
toxicities were classified according to the Common Terminology Criteria for Adverse Events, Version 4.0.
Clinical data, including liver function test results, radiological study findings, and RT parameters before and
after both courses of RT were retrieved for analysis. Using multivariate analysis, logistic regression was used
to identify the predictors of RILD, and Cox regression was performed to explore the prognostic factors for
overall survival (OS).
Results: Thirteen patients (36 %) developed RILD after reirradiation. Nine of them died because of progressive
liver failure without evidence of tumor progression and were categorized to have lethal RILD. A pretreatment
Child–Turcotte–Pugh (CTP) score ≥6 was the only predictor of RILD [odds ratio (OR): 15.83, p = 0.001] and lethal
RILD [OR: 72.56, p = 0.005]. In addition, a CTP score ≥6 and the presence of portal vein tumor thrombosis before
reirradiation were 2 prognostic factors for OS.
Conclusion: Despite a limited sample size, residual liver function using a preirradiation CTP score ≥6 is a clinical
parameter associated with an increased risk of RILD in patients requiring hepatic reirradiation.
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Introduction
Radiotherapy (RT) has become an increasingly employed
modality for treating hepatocellular carcinoma (HCC).
However, few data are available on the tolerance of the
liver to a second course of hepatic RT. The liver is
susceptible to radiation damage; therefore, classic or
nonclassic radiation-induced liver disease (RILD) has
been reported within weeks or months after the
administration of RT [1–3]. However, the guidelines
for avoiding RILD apply only to patients planning to
receive the first course of hepatic RT. Whether the
same guidelines are applicable to previously treated
patients is unclear. In particular, HCC is commonly
accompanied by liver cirrhosis [4–6]. Therefore,
investigating hepatic tolerance when a second course
of RT is required is critical.
Studies examining clinical parameters for ensuring the
safety of reirradiation for recurrent hepatoma are
currently lacking. Hence, to optimize patient selection,
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we conducted this study to identify risk factors associ-
ated with hepatic toxicities and treatment outcomes
after reirradiation. In this study, hepatic toxicities were
classified according to all RILD and lethal RILD events.
Our findings can provide information about the safety




In this study, we retrospectively analyzed the clinical
data of patients who received 2 courses of RT to the
liver between July 2004 and March 2014 at two hospi-
tals. The inclusion criteria were the following: (1) a diag-
nosis of HCC based on tissue proof or the typical
imaging appearance according to the criteria of the
European Association for the Study of the Liver [7]; (2)
administration of prior RT for intrahepatic HCC; (3) re-
sidual or recurrent hepatic tumors either within or out-
side the previous irradiation field; (4) residual or
recurrent tumors being unamenable to other treatments
such as surgery, transarterial chemoembolization, and
radiofrequency ablation; (5) an Eastern Cooperative On-
cology Group performance score of 0–1; and (6) a
Child-Pugh classification of A or B. The evaluation and
treatment policies for the included patients were
reviewed by a multidisciplinary team, and reirradiation
was recommended.
Comprehensive clinical data of all patients were
analyzed, including the age at reirradiation, the inter-
val between the 2 courses of RT, liver function test
(LFT) results, imaging study findings, and RT param-
eters before and after both courses of RT. The RT
parameters comprised the clinical target volume
(CTV), prescribed dose, normal liver reserve volume,
and mean liver dose. The LFT results were the hepa-
titis B virus (HBV) or hepatitis C virus infection sta-
tus; levels of serum alanine aminotransferase (ALT),
serum aspartate aminotransferase (AST), albumin,
total bilirubin, and alkaline phosphatase; prothrombin
time; and Child–Turcotte–Pugh (CTP) score. In total,
36 patients were included in this study; patient char-
acteristics are listed in Table 1. The median age was
66 years, with a range of 32–80 years.
Target delineation and RT planning
All patients underwent triphasic computed tomography
(CT) or magnetic resonance imaging before treatment.
The patients were immobilized using a vacuum bag with
motion control using abdominal compression. CT simu-
lation was performed using a 3-mm slice thickness with
contrast enhancement; the simulation range included
the entire liver, both lungs, and both kidneys. The
gross tumor volume (GTV) was contoured as visible
tumors on CT. The CTV was defined by leaving a
3–5-mm margin in three dimensions from the GTV
or from the area adjacent to visible tumors where
microscopic tumors were suspected. The planning
target volume (PTV) was delineated as a 5-mm mar-
gin added to the CTV in three dimensions. The nor-
mal liver reserve was defined as the entire liver
excluding all PTVs. According to recommended stan-
dards, the normal liver reserve was >700 mL, and
the mean dose was restricted to ≤23 Gy2 [8, 9]. In
addition, the median dose to any kidney was less
than 20 Gy2, the volume of the duodenum or
stomach receiving more than 50 Gy2 was restricted
to <1 mL, the mean dose to the esophagus was less
than 34Gy2, and the cumulative doses to the spinal
cord from two courses of RT was less than 60Gy2
[10]. The same technique and similar constraints
were used for both courses of RT.
All patients were treated using intensity-modulated
RT (IMRT) with or without image guidance or
image-guided tomotherapy. For patients treated with
IMRT, static and coplanar procedures were used,
whereas the X-ray energy depended on the tumor lo-
cation. In case of image-guided IMRT, tumor location
was verified with daily cone beam CT with or without
the implantation of fiducial markers. A dose–volume
histogram (DVH) was generated from a computerized
planning system for rigorous evaluation. The pre-
scribed doses for the 2 courses of RT in 36 patients
were 30–60 Gy and 10–60 Gy with a fraction size of
1.8–3 Gy; 2 of the 36 patients received stereotactic
body radiotherapy with a prescribed dose of 35 Gy in
5 fractions.
Follow-up and toxicity definition
A weekly clinical visit and routine LFT were rigorously
conducted during and after the RT course. After the reir-
radiation course, these patients underwent scheduled
LFTs and clinical assessment at least once in 2 weeks in
the initial 3 months and monthly follow-up thereafter.
For any patient developing ≥ grade 3 hepatic toxicities or
rapid deterioration of liver function resulting in coagu-
lopathy or encephalopathy, RT was discontinued imme-
diately. When the LFT values deteriorated, the patients
were admitted for daily evaluation and supportive care.
All toxicities were classified according to the Common
Terminology Criteria for Adverse Events (CTCAE),
Version 4 [11]. Classic RILD was defined as anicteric
hepatomegaly and ascites with more than double the
upper limit of the normal level of alkaline phosphate [6].
Moreover, according to the CTCAE criteria, nonclassic
RILD was defined as ≥ grade 3 hepatic toxicities, with
more than 3 times the upper limit of the normal level of
blood bilirubin or more than 5 times the upper limit of
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Table 1 Characteristics of all patients
Patients with RILD Patients without RILD




Median age at reirradiation 64 71
(range, 32 to 77) (range, 33 to 89)










Category of previous hepatitis
Hepatitis B infection 6 10
Hepatitis C infection 2 6
non-HBV and non-HCV induced 5 7
CTP scores before the 2nd RT 6.3 ± 1.1 5.2 ± 0.5





Mean prescribed dose (EQD2, Gy) 49.5 ± 8.2 52.5 ± 5.7
Mean CTV (cm3) 392.9 ± 407.0 345.2 ± 565.0
Mean PTV (cm3) 257.9 ± 207.8 314.4 ± 480.7
Mean normal liver dose (EQD2, Gy) 20.8 ± 11.3 20.1 ± 8.2
Mean normal liver volume (cm3) 1255.5 ± 569.4 926.5 ± 242.4
2nd RT parameters
Mean prescribed dose (EQD2, Gy) 32.9 ± 14.5 40.6 ± 12.8
Mean CTV (cm3) 139.1 ± 150.2 211.3 ± 343.1
Mean PTV (cm3) 257.9 ± 207.8 314.4 ± 480.7
Mean normal liver dose (EQD2, Gy) 12.3 ± 6.6 10.2 ± 5.5
Mean normal liver volume (cm3) 1173.4 ± 622.2 992.5 ± 196.1
Mean cumulative prescribed dose (EQD2, Gy) 80.9 ± 17.8 94.4 ± 13.9
Mean cumulative normal liver dose (EQD2, Gy) 32.5 ± 15.1 30.5 ± 9.6
Abbreviation: RILD radiation-induced liver disease, TNM stage was evaluated before reirradiation; TAE transarterial embolization, TACE transarterial chemo-embolization,
RFA radiofrequency ablation, Cryo cryotherapy, RT radiotherapy, CTV clinical tumor volume, PTV planning target volume, EQD2 biologically equivalent doses calculated
in 2Gy
Note: abutting score: if reirradiation applied to a PTV separated from the previous PTV because the tumors were located at different segments, this situation was
defined as out-field reirradiation (score = 0). For patients receiving reirradiation at the same or adjacent segment, the 2nd PTVs might be partially included in the
previous PTV (score 1), or completely included (score 2)
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the normal levels of ALT or AST [12]. Lethal RILD was
defined as death directly caused by RT-related progres-
sive hepatic failure before or without evidence of tumor
progression.
In addition, we examined the impact of location of the
two PTVs on the effect of RILD. Irradiation applied to
recurrent tumors situated inside the previous PTV
was defined as in-field reirradiation. Conversely,
irradiation applied to a PTV separated from the pre-
vious PTV because the tumors were located at differ-
ent segments was defined as out-field reirradiation
(N = 9). For patients receiving reirradiation at the
same or adjacent segment (N = 27), we proposed an
abutting score for classify the location of two PTVs
when assessing the impact of volume effect, as
described in Table 1.
Statistical analyses
The primary analysis was identifying the clinical pa-
rameters that could predict RILD and lethal RILD.
The secondary analysis was identifying prognostic factors
associated with survival after reirradiation. Logistic regres-
sion analysis was used to identify the predictors of RILD.
Variables with a statistical significance in the univariate
analysis were included in the multivariate analysis. Overall
survival (OS) was defined as the time from the com-
mencement of the second course of RT to the date of
death from any cause or the final follow-up. Survival
curves were calculated using the Kaplan–Meier method
and log-rank test. Cox regression was performed to
explore the prognostic factors for OS. The variables
analyzed included age, the pretreatment LFT values (CTP
score, albumin, total bilirubin, ascites), PTV, normal liver
dose of the reirradiation, cumulative normal liver dose,
duration, location of the two PTVs, and the presence of
portal vein tumor thrombosis (PVTT). A 2-sided p value
of <0.01 was considered statistically significant. All
statistical analyses were performed using SPSS 13.0 for
Windows (SPSS Inc., Chicago, IL, USA).
Results
General outcomes
The mean follow-up duration after reirradiation was
17 months (range, 3 to 74 months). Thirteen patients
(36 %) developed RILD within 3 months after the initi-
ation of reirradiation. All events were categorized as
nonclassic RILD according to their clinical manifest-
ation. Of the 13 patients, 2 could not complete the allo-
cated RT regimen because of hepatic toxicities, and the
prescribed doses were 20 Gy in 10 fractions and 21.6 Gy
in 12 fractions. There was no evidence to show the con-
tinuous deterioration of liver function after the 1st
course of RT. Although the previous RT might lead to a
subclinical change of liver function, the RILD was
mainly attributed to the consequence of reirradiation.
The details of both courses of RT are summarized in
the Appendix. We normalized the RT dose by using
biologically equivalent doses calculated in 2 Gy as the
α/β ratio of 15 for HCC [13] and 8 for the adjacent
hepatic tissues [10]. In brief, the mean irradiation
doses of the second course of RT for the hepatic tumor
and normal liver tissue were 37.52 Gy15 (range, 10–
58.68 Gy15) and 10.83 Gy8 (range, 2.5–23.97 Gy8),
respectively. Moreover, the mean cumulative doses to
the hepatic tumor and normal liver tissue were
87.70 Gy15 (range, 60.47–117.37 Gy15) and 31.11 Gy8
(range, 9.15–62.84 Gy8), respectively. The median
interval between the 2 courses of RT was 11.0 months
(range, 1–47 months).
Among the 13 patients with RILD, 4 had transient
grade 3 hepatic toxicity, and the LFT values eventually
returned to the normal range within 1 month after the
completion of RT. Nine patients had lethal RILD
without evidence of intrahepatic tumor progression; 8
patients died of fulminant hepatic failure within
3 months, and the remaining patient died of progressive
liver failure 5 months after reirradiation. Furthermore,
2 patients did not complete the prescribed RT course
because of a rapid deterioration of hepatic function
during treatment, which LFT showed more than 5
times the upper limit of the normal levels of ALT or
AST or more than 3 times the upper limit of the
normal level of blood bilirubin. In addition to the 13
patients with RILD, 2 patients died of massive bleed-
ing caused by esophageal and gastric varices within
6 months after reirradiation, which was a fatal com-
plication of portal hypertension and classified as non-
RILD related death. The other treatment-related ad-
verse events such as RT-induced gastrointestinal
bleeding, angiocholitis, and biliary stricture were not
observed in this cohort.
Risk factors for RILD and lethal RILD
To investigate the risk factors for RILD, clinical data,
including the pretreatment LFT values, CTP score,
and RT parameters before both courses of RT, were
analyzed. As shown in Table 2, several pretreatment
LFT values and clinical parameters were associated
with RILD in univariate analysis. Multivariate analysis
revealed that a pretreatment CTP score ≥6 was a pre-
dictor of RILD [odds ratio (OR): 15.83, 95 % confi-
dence interval (CI): 2.95–85.08, p = 0.001]. The results
of univariate and multivariate analyses for lethal RILD
are summarized in Table 3. A preirradiation CTP
score ≥6 was the only factor associated with lethal
RILD [OR: 72.56, 95 % CI: 3.650–1442.252, p = 0.005].
No statistical differences were observed among all
Huang et al. Radiation Oncology  (2016) 11:89 Page 4 of 9
dosimetric parameters between patients with and those
without RILD. In addition, the abutting score for the two
PTVs and the treatment interval did not affect RILD.
Furthermore, the pretreatment LFT before the 1st course
of RT and normal liver dose or volume of the first RT
course did not affect the occurrence of RILD after
reirradiation (Appendix).
Prognostic factors for OS
At the time of this analysis, 32 patients died of disease
progression with or without hepatic failure. Patients with
RILD exhibited a shorter OS than did those without
RILD, with the median survival being 5.7 and
29.0 months, respectively (p < 0.001; Fig. 1). The median
survival decreased to 3.8 months in patients with
lethal RILD. In multivariate analysis, the presence of
PVTT [hazard ratio (HR): 12.41, 95 % CI: 2.05–12.41,
p < 0.001) and a CTP score ≥6 (HR: 8.79, 95 % CI:
1.48–6.74, p = 0.003) before reirradiation were prog-
nostic factors. As depicted in Fig. 1, the median OS
of patients with and without PVTT was 5 months
and 22 months, respectively (p < 0.001), whereas that
of patients with CTP scores of ≥6 and 5 was 4 months
and 18 months (p < 0.001), respectively. No statistical
difference was observed regarding OS for other clin-
ical parameters, such as age, the irradiation interval,
and the dosimetric parameters.
Discussion
In advanced HCC, RT is assumed to delay the time to
tumor progression and resolves vascular damage caused
by PVTT. However, the benefits are reduced by the
increased risk of RT-related hepatic toxicities. Several
studies have reported clinical parameters associated with
RILD [14–18]; however, currently, no guidelines exist re-
garding hepatic tolerance or risk factors for RILD after
reirradiation. This study is the first to reveal that a CTP
score ≥6 is associated with an increased risk of RILD
and predicts the occurrence of lethal RLID. In particular,
the estimated OR was more than 10-fold higher than
that of patients with a CTP score of 5. In addition, a
high mortality rate can be anticipated in patients with a
CTP score ≥6. In our study, patients with a pretreatment
CTP score ≥6 had a median OS of less than 6 months;
Table 2 Risk factors associated with RILD after reirradiation
Variables RILD (+) RILD (−) Univariate Multivariate
p value p value OR 95 % CI
Total number 13 23
Liver function before 2nd RT
Total bilirubin ≧2.0 mg/dL 4 0 0.016
Albumin ≦3.5 g/dL 8 4 0.007
Presence of ascites 3 1 0.086
INR ≧1.71 0 0
CTP score ≧6 10 4 <0.0001 0.001 15.833 2.947 ~ 85.075
Presence of PVTT 8 5 0.017
AST/ALT ≧3x of upper normal limit 5 1 0.088
Hepatitis
Hepatitis B infection 6 10 0.877
Hepatitis C infection 2 6 0.458
RT parameters of 2nd RT
Mean CTV (cm3) 158.8 ± 157.9 204.2 ± 348.7 0.740
Mean PTV (cm3) 257.9 ± 207.8 314.4 ± 480.7 0.260
Mean normal liver dose (EQD2, Gy8) 12.0 ± 6.8 10.2 ± 4.8 0.726
Mean normal liver volume (cm3) 1173.4 ± 622.2 992.5 ± 196.1 0.332
Interval between 2 courses (month) 8.1 ± 8.1 12.6 ± 12.3 0.247
Mean cumulative normal liver dose (EQD2, Gy8) 32.0 ± 15.0 30.6 ± 9.7 0.233
Mean cumulative prescribed dose (EQD2, Gy15) 82.8 ± 15.9 90.6 ± 15.4 0.065
Abutting score for two PTV 1.3 ± 0.9 1.1 ± 0.7 0.548
Abbreviation: RILD radiation-induced liver disease, OR odds ratio, CI confidence interval, CTP Child-Turcotte-Pugh, PVTT portal vein tumor thrombosis, AST aspartate
aminotransferase, ALT alanine aminotransferase, CTV clinical tumor volume, NS no significance, EQD2 biologically equivalent doses calculated in 2Gy
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therefore, tailored selection is essential for patients
requiring a second course of RT.
This study analyzed several pretreatment LFT parame-
ters and concluded that the CTP score, which is widely
used for the clinical assessment of liver cirrhosis, was a
stronger predictor of hepatic toxicities than the other
parameters. In addition, our study revealed that the
duration between the 2 courses of RT and the dosimetric
parameters did not affect the risk of hepatic toxicities,
implying that residual liver function still plays a major
role in determining the tolerance to reirradiation. This
finding is consistent with the findings of several studies
[3, 12, 14–17, 19, 20]. Yoon reported no correlation
between RILD and DVH parameters, including the total
Table 3 Risk factors associated with lethal RILD after reirradiation
Variables Lethal RILD (+) Lethal RILD (−) Univariate Multivariate
p value p value OR 95 % CI
Total number 9 27
Liver function before 2nd RT
Total bilirubin ≧2.0 mg/dL 4 0 0.002
Albumin ≦3.5 g/dL 6 6 0.001
Presence of ascites 3 1 0.014
INR ≧1.71 0 0
CTP score ≧6 8 6 <0.001 0.005 72.5554 3.650 ~ 1442.252
Presence of PVTT 7 6 0.003
AST/ALT ≧3x of upper normal limit 4 2 0.121
Hepatitis
Hepatitis B infection 5 11 0.439
Hepatitis C infection 1 7 0.355
RT parameters of 2nd RT
Mean CTV (cm3) 195.2 ± 166.9 186.4 ± 331.7 0.806
Mean PTV (cm3) 315.5 ± 224.5 285.7 ± 447.7 0.890
Mean normal liver dose (EQD2, Gy8) 9.7 ± 6.8 11.3 ± 5.2 0.019
Mean normal liver volume (cm3) 1305.8 ± 687.6 975.2 ± 210.5 0.078
Interval between 2 courses (month) 6.0 ± 8.5 12.7 ± 11.4 0.119
Mean cumulative normal liver dose (EQD2, Gy8) 27.9 ± 12.5 32.2 ± 11.5 0.221
Mean cumulative prescribed dose (EQD2, Gy15) 75.0 ± 12.7 92.1 ± 14.7 0.005
Abutting score for two PTV 1.4 ± 0.8 1.1 ± 0.8 0.824


































Fig. 1 Overall survival according to the occurrence of RILD, pre-reirradiation CTP score, and presence of PVTT. Abbreviation: RILD, radiation-induced
liver disease; CTP, Child-Turcotte-Pugh; PVTT, portal vein tumor thrombosis
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liver volume, mean liver dose, V30, normal tissue com-
plication probability (NTCP), and equivalent uniform
dose [15]. Cheng et al. proposed that patients with HCC
having HBV infection and a Child–Pugh class of B have
a high risk of RILD [14]. Liang et al. suggested that the
severity of hepatic cirrhosis is a major prognostic factor
for RILD. In addition, some studies have suggested that
the indocyanine green retention rate at 15 min (ICG-
R15) is an accurate tool for predicting RILD [15, 16].
Lee et al. indicated that the CTP score is a more reliable
predictor of RILD than is the ICG-R15 [21]. By
contrast, Pan et al. conducted quantitative analyses of
normal tissue in a clinic and suggested applying stric-
ter dose constraints to RT for HCC than for meta-
static hepatic tumors, namely mean normal liver
doses of less than 28 Gy for HCC and less than
32 Gy for liver metastases for therapeutic partial liver
RT (in 2-Gy fractions) [22]. To reach a widely ac-
cepted consensus, clinical trials analyzing comprehen-
sive DVH data, clinical parameters, and the HBV titer
should be conducted to determine patients with a
high risk of RILD after reirradiation.
Although our study showed no impact of location
of the two PTVs on RILD, the effect of the dose
distribution pattern on outcomes requires further in-
vestigation. If recurrent tumors are situated inside
the previous PTV, the surrounding hepatic tissues
receive a summation of doses from both courses of
RT. Dawson et al. proposed that a partial liver can
tolerate more than 100 Gy if the volume is smaller
than 25 % [5]. By contrast, the cumulative low dose
volume is larger when recurrent tumors are far from
the previous PVTT. According to a similar NTCP
model [5], two-thirds of the total liver volume was
assumed to tolerate doses of less than 48 Gy,
whereas the total liver volume can tolerate doses of
less than 32 Gy. In this study, we compared the
cumulative dose to the normal liver rather than the
detailed DVH profile because of the difficulty of
summing DVHs from both courses of RT. Therefore,
comprehensive DVH data should be retrieved for
future analysis.
PVTT is an established prognostic factor for sur-
vival in patients with HCC receiving hepatic RT [3].
Our study revealed that PVTT had a significant ef-
fect on OS after reirradiation. Therefore, in patients
with PVTT, the risk of shortened survival should be
considered before reirradiation. In a retrospective
study of a cohort of 46 patients with HCC receiving
RT [3], Furuse et al. reported that PVTT exerted
substantial effects on acute adverse hepatic toxicities,
survival, and tumor response. They also confirmed
that acute hepatic toxicities, including hyperbilirubi-
nemia and hypoalbuminemia, were critical factors
affecting survival. Therefore, in the future, we plan
to clarify the association between the grade of the
tumor thrombus and adverse hepatic events or treat-
ment outcomes.
Our study results should be interpreted with cau-
tion. First, the results of this retrospective study with
a limited sample size from 2 institutes should be pro-
spectively validated using different irradiation schemes
and patient populations. In addition, complete param-
eters of liver function such as gamma glutamyl trans-
ferase or virus titers were imperative to monitor the
hepatic damage. Furthermore, the place of SBRT was
still unclear in this study because of different bio-
logical dose effect compared to conventional radio-
therapy. A prospective trial using SBRT for recurrent
hepatic tumor is essential to maximize the therapeutic
ratio. Finally, the conclusion can be strengthened by
collecting and comparing more comprehensive DVH
parameters. Thus, a modified NTCP model can be
designed for obtaining an accurate score of the risk
of RILD following reirradiation. Nonetheless, our
study has implications for decision-making regarding
initiating the second course of hepatic RT or stratify-
ing patients in clinical trials. With more careful and
thorough evaluation, this study can help radiation on-
cologists more meticulously re-treat patients with
HCC, and survival benefits can be expected in pa-
tients who do not develop RILD. Early prediction of
potential hepatic toxicities would enable administering
individualized therapy to patients requiring a second
course of hepatic RT.
Conclusion
Although this study included low number of patients
into the analysis, a pretreatment CTP score ≥6 is as-
sociated with an increased risk of RILD and lethal
RILD in patients requiring a second course of hepatic
RT. Patients with RILD have a high mortality rate,
implying that residual liver function plays a crucial
role in determining the tolerance to reirradiation and
survival after treatment. A multicenter prospective
study is required to examine additional comprehen-
sive risk factors for RILD.
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Appendix
Abbreviation
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CT, computed
tomography; CTCAE, Common Terminology Criteria for Adverse Events; CTP,
Child-Turcotte-Pugh; CTV, clinical target volume; DVH, dose–volume histogram;
GTV, gross tumor volume; HBV, hepatitis B virus; HCC, hepatocellular carcinoma;
ICG-R15, indocyanine green retention rate at 15 min; LFT, liver function test;
NTCP, normal tissue complication probability; OS, overall survival; PTV, planning
target volume; PVTT, portal vein tumor thrombosis; RILD, radiation-induced liver
disease; RT, radiotherapy
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